Author

Yang Dai

Observed name: Y. Dai

Institution: Alexion Pharmaceuticals (United States)

Observed institutions: Alexion Pharmaceuticals (United States), AstraZeneca (United States)

ORCID: 0009-0001-6070-0645

Observed ORCID: 0009-0001-6070-0645

OpenAlex ID: A5025530766

A prospective phase 2 clinical trial of a C5a complement inhibitor for acute GVHD with lower GI tract involvement

2023 · Rohtesh S. Mehta, Haris Ali, et al. · Bone Marrow Transplantation · 10

A Phase 2a, Randomized, Open-Label Study to Evaluate Multiple Dosing Regimens of Subcutaneous ALXN1820 in Adult Patients with Sickle Cell Disease

2022 · Yang Dai, Kelley Hill, et al. · Blood · 10

S267: Properdin-blocking Antibodies Attenuate Complement Alternative Pathway Activation Triggered by Cell-free Heme in Sickle Cell Disease Models

2022 · T. Trovati Maciel, R. Cofiell, et al. · HemaSphere · 3

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of ALXN1820 (Tarperprumig) in Healthy Adults: Results of a Phase I Study

2025 · Avner Sandhu, Tong Shen, et al. · Clinical and Translational Science · 2

Works count: 4

Citation count: 25

H-index: 3

I10-index: 2